Business
Cannabics Pharmaceuticals to Participate in the International Cannabis Research Society Annual Forum in Leiden, the Netherlands
Cannabics Pharmaceuticals to Participate in the International Cannabis Research Society Annual Forum in Leiden, the Netherlands.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals to Participate in the International Cannabis Research Society Annual Forum in Leiden, the Netherlands\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals to Participate in the International Cannabis Research Society Annual Forum in Leiden, the Netherlands\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, June 26, 2018\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, June 26, 2018 /PRNewswire/ --  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabis medicine focused on cancer and its side effects, announced today that senior members of its scientific team will be attending the International Cannabinoid Research Society conference, to be held in Leiden, the Netherlands July 1st – 4th 2018, and will be available for one on one meetings.\n\n\nThe International Cannabinoid Research Society, ICRS, a non-political organization, is dedicated to scientific research in all fields of cannabinoids, ranging from biochemical, chemical and physiological studies of the endogenous cannabinoid system. It also acts as a source for impartial information on Medical Cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research.\n\nIn attendance will be Dr Haleli Sharir, Dr Nir Kfir, and Dr. Eyal Ballan, the company's Co-Founder and CTO. \n\nDr. Sharir is reknown for her role in possibly identifying a new cannabinoid receptor, GPR55. As a member of a research group, it was observed that human GPR55 can be activated by several types of cannabinoids. The research was funded by the National Institute of Health (NIH/NIDA), and results are available through the National Center for Biotechnology Information (NCBI).\n\nDr. Kfir's background is in molecular genetics, specializing in RNA processing and chromatin organization. In previous work, he focused on high throughput screening and on researching new chemotherapy treatments that restore a cancer cell's ability to undergo \"programmed cell death\".\n\nEyal Ballan, ...